secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001171843-22-007046
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates
--------------------------------------------------------------------------------

- Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.
- Cash $24.2M at Sep 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $14.4M in nine months.
- Five abstracts accepted at SITC 2022; R&D day Nov 10, 2022 featuring external experts.
- R&D expenses rose to $6.15M from $3.33M in Q3 2021 due to internal cGMP manufacturing scale-up.
- No revenue or guidance; clinical-stage biotech advancing allogeneic iNKT cell therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/0001171843-22-007046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/f8k_110322.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer